Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 104 articles:
HTML format



Single Articles


    January 2023
  1. CHEN WC, Li JR, Wang SS, Chen CS, et al
    Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study.
    PLoS One. 2023;18:e0279981.
    PubMed     Abstract available


  2. RAKAUSKAS A, Peters M, Martel P, van Rossum PSN, et al
    Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study.
    PLoS One. 2023;18:e0280262.
    PubMed     Abstract available


  3. HAN JH, Chung DH, Cho MC, Ku JH, et al
    Natural history of incidentally diagnosed prostate cancer after holmium laser enucleation of the prostate.
    PLoS One. 2023;18:e0278931.
    PubMed     Abstract available


  4. BRAGA-BASARIA M, Travison TG, Taplin ME, Lin A, et al
    Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.
    PLoS One. 2023;18:e0281508.
    PubMed     Abstract available


  5. NATKIN R, Pennanen P, Syvala H, Blauer M, et al
    Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.
    PLoS One. 2023;18:e0281645.
    PubMed     Abstract available


  6. CHEN WH, Lee YK, Kuo HC, Wang JH, et al
    Oncological and functional outcomes of high-risk and very high-risk prostate cancer patients after robot-assisted radical prostatectomy.
    PLoS One. 2023;18:e0282494.
    PubMed     Abstract available


  7. HASANNEJADASL H, Roumen C, van der Poel H, Vanneste B, et al
    Development and external validation of multivariate prediction models for erectile dysfunction in men with localized prostate cancer.
    PLoS One. 2023;18:e0276815.
    PubMed     Abstract available


  8. DERIS A, Sohrabi-Haghighat M
    Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
    PLoS One. 2023;18:e0282646.
    PubMed     Abstract available


  9. DUENWEG SR, Brehler M, Bobholz SA, Lowman AK, et al
    Comparison of a machine and deep learning model for automated tumor annotation on digitized whole slide prostate cancer histology.
    PLoS One. 2023;18:e0278084.
    PubMed     Abstract available


  10. TSAI TH, Chu TW, Lin TH, Hsieh TF, et al
    Ethnic differences in the age-related distribution of serum prostate-specific antigen values: A study in a Taiwanese male population.
    PLoS One. 2023;18:e0283040.
    PubMed     Abstract available


    January 2022
  11. CHAPLOW ZL, Lucas AR, Grainger E, Simpson C, et al
    Social cognitive outcomes are associated with improvements in mobility performance following lifestyle intervention in prostate cancer patients undergoing androgen deprivation therapy.
    PLoS One. 2022;17:e0263136.
    PubMed     Abstract available


  12. NYAMSAMBUU A, Khan MA, Zhou X, Chen HC, et al
    Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion.
    PLoS One. 2022;17:e0261341.
    PubMed     Abstract available


  13. KASIVISVANATHAN V, Chan VW, Clement KD, Levis B, et al
    A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer.
    PLoS One. 2022;17:e0263345.
    PubMed     Abstract available


  14. SHU W, Tao W, Chunyan H, Jie F, et al
    Preoperative nutritional evaluation of prostate cancer patients undergoing laparoscopic radical prostatectomy.
    PLoS One. 2022;17:e0262630.
    PubMed     Abstract available


  15. LARKIN D, Birtle AJ, Bradley L, Dey P, et al
    A systematic review of disease related stigmatization in patients living with prostate cancer.
    PLoS One. 2022;17:e0261557.
    PubMed     Abstract available


  16. ROGGERO CM, Esser V, Duan L, Rice AM, et al
    Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity.
    PLoS One. 2022;17:e0258876.
    PubMed     Abstract available


  17. FORYS U, Nahshony A, Elishmereni M
    Mathematical model of hormone sensitive prostate cancer treatment using leuprolide: A small step towards personalization.
    PLoS One. 2022;17:e0263648.
    PubMed     Abstract available


  18. SHAO W, Zhang H, Qi H, Zhang Y, et al
    The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis.
    PLoS One. 2022;17:e0263918.
    PubMed     Abstract available


  19. ZHANG H, Yang H, Bandyopadhyay S, Milano MT, et al
    Increased risk of high-grade prostate cancer among testicular cancer survivors.
    PLoS One. 2022;17:e0263573.
    PubMed     Abstract available


  20. MARSDEN T, McCartan N, Brown L, Rodriguez-Justo M, et al
    The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.
    PLoS One. 2022;17:e0259672.
    PubMed     Abstract available


  21. SIEWE N, Friedman A
    Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
    PLoS One. 2022;17:e0262453.
    PubMed     Abstract available



  22. Expression of Concern: Akt Mediates Metastasis-Associated Gene 1 (MTA1) Regulating the Expression of E-cadherin and Promoting the Invasiveness of Prostate Cancer Cells.
    PLoS One. 2022;17:e0266930.
    PubMed    


  23. LIN SF, Lin HC, Lee MY, Keller JJ, et al
    Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study.
    PLoS One. 2022;17:e0266771.
    PubMed     Abstract available


  24. LEE JJB, Lee E, Choi WH, Kim J, et al
    Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy.
    PLoS One. 2022;17:e0265143.
    PubMed     Abstract available


  25. TZELVES L, Manolitsis I, Varkarakis I, Ivanovic M, et al
    Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.
    PLoS One. 2022;17:e0265127.
    PubMed     Abstract available


  26. LEE ST, Wong PF, He H, Hooper JD, et al
    Correction: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling.
    PLoS One. 2022;17:e0268234.
    PubMed     Abstract available


  27. WIAFE E, Mensah KB, Oosthuizen F, Bangalee V, et al
    A pilot study of the knowledge, awareness and perception of prostate cancer in Ghanaian women.
    PLoS One. 2022;17:e0267797.
    PubMed     Abstract available


  28. LIN Z, Zhang Z, Ye X, Zhu M, et al
    Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer.
    PLoS One. 2022;17:e0263291.
    PubMed     Abstract available



  29. Retraction: Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.
    PLoS One. 2022;17:e0268981.
    PubMed    


  30. CLARKE CS, Hunter RM, Gabrio A, Brawley CD, et al
    Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
    PLoS One. 2022;17:e0269192.
    PubMed     Abstract available


  31. CHUNG DY, Jung HD, Kim DK, Lee MH, et al
    Outcomes of Retzius-sparing versus conventional robot-assisted radical prostatectomy: A KSER update series systematic review and meta-analysis.
    PLoS One. 2022;17:e0268182.
    PubMed     Abstract available


  32. MOKOATLE M, Mapiye D, Marivate V, Hayes VM, et al
    Discriminatory Gleason grade group signatures of prostate cancer: An application of machine learning methods.
    PLoS One. 2022;17:e0267714.
    PubMed     Abstract available


  33. HARKE NN, Wagner C, Hermann RM, Hadaschik BA, et al
    Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
    PLoS One. 2022;17:e0269827.
    PubMed     Abstract available


  34. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2022;17:e0270734.
    PubMed     Abstract available


  35. LI JR, Wang SS, Chen CS, Cheng CL, et al
    Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study.
    PLoS One. 2022;17:e0270292.
    PubMed     Abstract available


  36. WANG BJ, Huang SH, Kao CL, Muller CJF, et al
    Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
    PLoS One. 2022;17:e0270803.
    PubMed     Abstract available


  37. SHAHAIT M, Abu-Hijlih R, Salamat A, Abou Heidar N, et al
    Bone marrow involvement in patients with metastatic castration sensitive prostate cancer.
    PLoS One. 2022;17:e0270956.
    PubMed     Abstract available


  38. ALBERTS I, Butikofer L, Rominger A, Afshar-Oromieh A, et al
    A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
    PLoS One. 2022;17:e0270269.
    PubMed     Abstract available


  39. HENKEL M, Horn T, Leboutte F, Trotsenko P, et al
    Initial experience with AI Pathway Companion: Evaluation of dashboard-enhanced clinical decision making in prostate cancer screening.
    PLoS One. 2022;17:e0271183.
    PubMed     Abstract available


  40. OWOO B, Ninnoni JPK, Ampofo EA, Seidu AA, et al
    "I always find myself very tired and exhausted": The physical impact of caring; a descriptive phenomenological study of the experiences of prostate cancer caregivers in Cape Coast, Ghana.
    PLoS One. 2022;17:e0268627.
    PubMed     Abstract available


  41. KATZENDORN O, von Klot CAJ, Mahjoub S, Faraj Tabrizi P, et al
    Combination of PI-RADS score and mRNA urine test-A novel scoring system for improved detection of prostate cancer.
    PLoS One. 2022;17:e0271981.
    PubMed     Abstract available


  42. GUIN S, Liaw BK, Jun T, Ayers K, et al
    Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.
    PLoS One. 2022;17:e0264800.
    PubMed     Abstract available


  43. BAKER A, Khalid M, Uddin I, Khan MS, et al
    Targeted non AR mediated smart delivery of abiraterone to the prostate cancer.
    PLoS One. 2022;17:e0272396.
    PubMed     Abstract available


  44. HELFAND BT, Paterakos M, Wang CH, Talaty P, et al
    The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer.
    PLoS One. 2022;17:e0273782.
    PubMed     Abstract available


  45. SHAH YB, Shaver AL, Kelly WK, Lu-Yao G, et al
    A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.
    PLoS One. 2022;17:e0273826.
    PubMed     Abstract available


  46. PANTELIDOU M, Caglic I, George A, Blyuss O, et al
    Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study.
    PLoS One. 2022;17:e0274014.
    PubMed     Abstract available


  47. BLOEMBERG J, Trauzettel F, Coolen B, Dodou D, et al
    Design and evaluation of an MRI-ready, self-propelled needle for prostate interventions.
    PLoS One. 2022;17:e0274063.
    PubMed     Abstract available


  48. CHEN C, Lin M, Yu D, Qin W, et al
    Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials.
    PLoS One. 2022;17:e0275176.
    PubMed     Abstract available


  49. TAKESHIMA Y, Yamada Y, Takemura K, Kimura N, et al
    The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy.
    PLoS One. 2022;17:e0275069.
    PubMed     Abstract available


  50. JAGARLAMUDI KK, L S, M Z, J O, et al
    Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.
    PLoS One. 2022;17:e0275444.
    PubMed     Abstract available


  51. KANAO K, Takahashi T, Umezawa Y, Okabe T, et al
    Efficacy of abiraterone acetate for high-risk hormone-naive metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
    PLoS One. 2022;17:e0276081.
    PubMed     Abstract available


  52. MAPANGA W, Norris SA, Craig A, Pumpalova Y, et al
    Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa.
    PLoS One. 2022;17:e0276050.
    PubMed     Abstract available


  53. RISE K, Tessem MB, Drablos F, Rye MB, et al
    FunHoP analysis reveals upregulation of mitochondrial genes in prostate cancer.
    PLoS One. 2022;17:e0275621.
    PubMed     Abstract available


  54. MEURMAN JH, Kallmen H, Andersson LC, Yucel-Lindberg T, et al
    Prevalence of cancer in relation to signs of periodontal inflammation.
    PLoS One. 2022;17:e0276375.
    PubMed     Abstract available


  55. BARBIER MC, Tomonaga Y, Menges D, Yebyo HG, et al
    Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
    PLoS One. 2022;17:e0277282.
    PubMed     Abstract available


  56. VILJOEN B, Hofman MS, Chambers SK, Dunn J, et al
    Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study.
    PLoS One. 2022;17:e0276063.
    PubMed     Abstract available


  57. MYERS MS, Kosmacek EA, Chatterjee A, E Oberley-Deegan R, et al
    CT vs. bioluminescence: A comparison of imaging techniques for orthotopic prostate tumors in mice.
    PLoS One. 2022;17:e0277239.
    PubMed     Abstract available


  58. MENA E, Shih J, Chung JY, Jones J, et al
    Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0277407.
    PubMed     Abstract available


  59. ORRASON AW, Westerberg M, Albertsen P, Styrke J, et al
    Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy.
    PLoS One. 2022;17:e0277784.
    PubMed     Abstract available


  60. PRATT NL, Cicuttini FM, Wang Y, Graves SE, et al
    No increased risk of cancer associated with metal-on-metal or ceramic-on-ceramic procedures compared to other bearing surfaces in patients with total hip arthroplasty: A nationwide linked registry cohort analysis of 167,837 patients.
    PLoS One. 2022;17:e0278241.
    PubMed     Abstract available


  61. KARKEET RM, Zekri AN, Sayed-Ahmed MM, Sherif GM, et al
    The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
    PLoS One. 2022;17:e0278282.
    PubMed     Abstract available


  62. HART JE, Mohan S, Davies KG, Ferneyhough B, et al
    Hexapeptides from mammalian inhibitory hormone hunt activate and inactivate nematode reproduction.
    PLoS One. 2022;17:e0278049.
    PubMed     Abstract available


  63. VYAS N, Brunckhorst O, Fox L, Van Hemelrijck M, et al
    Undergoing radical treatment for prostate cancer and its impact on wellbeing: A qualitative study exploring men's experiences.
    PLoS One. 2022;17:e0279250.
    PubMed     Abstract available


  64. DING H, He C, Tong Y, Fang Q, et al
    Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    PLoS One. 2022;17:e0279286.
    PubMed     Abstract available


    January 2021
  65. ZIAYEE F, Ullrich T, Blondin D, Irmer H, et al
    Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    PLoS One. 2021;16:e0249532.
    PubMed     Abstract available


  66. KHAIRNAR R, Pugh SL, Sandler HM, Lee WR, et al
    Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    PLoS One. 2021;16:e0249123.
    PubMed     Abstract available


  67. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed     Abstract available


  68. ZHANG P, Tan X, Zhang D, Gong Q, et al
    Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
    PLoS One. 2021;16:e0249951.
    PubMed     Abstract available


  69. YADAV MP, Ballal S, Sahoo RK, Tripathi M, et al
    Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    PLoS One. 2021;16:e0251375.
    PubMed     Abstract available


  70. SAIDOVA AA, Potashnikova DM, Tvorogova AV, Paklina OV, et al
    Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
    PLoS One. 2021;16:e0251961.
    PubMed     Abstract available



  71. Retraction: Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer.
    PLoS One. 2021;16:e0253350.
    PubMed    


  72. LOUGHNEY L, McGowan R, O'Malley K, McCaffrey N, et al
    Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study.
    PLoS One. 2021;16:e0253018.
    PubMed     Abstract available


  73. PAROL-KULCZYK M, Gzil A, Maciejewska J, Bodnar M, et al
    Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.
    PLoS One. 2021;16:e0253112.
    PubMed     Abstract available


  74. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0253021.
    PubMed     Abstract available


  75. GUERRIERO I, Ramberg H, Sagini K, Ramirez-Garrastacho M, et al
    Implication of beta2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells.
    PLoS One. 2021;16:e0253828.
    PubMed     Abstract available


  76. JIANG X, Renkema H, Smeitink J, Beyrath J, et al
    Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
    PLoS One. 2021;16:e0254315.
    PubMed     Abstract available


  77. SALMI F, Maachi F, Tazzite A, Aboutaib R, et al
    Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
    PLoS One. 2021;16:e0254101.
    PubMed     Abstract available


  78. RUNDLE AG, Sadasivan SM, Chitale DA, Gupta NS, et al
    Racial differences in the systemic inflammatory response to prostate cancer.
    PLoS One. 2021;16:e0252951.
    PubMed     Abstract available


  79. ZHANG H, Doucette C, Yang H, Bandyopadhyay S, et al
    Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.
    PLoS One. 2021;16:e0253936.
    PubMed     Abstract available


  80. BARRY DELONGCHAMPS N, Schull A, Anract J, Abecassis JP, et al
    Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
    PLoS One. 2021;16:e0252040.
    PubMed     Abstract available


  81. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available


  82. FALLARA G, Gedeborg R, Bill-Axelson A, Garmo H, et al
    A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
    PLoS One. 2021;16:e0255239.
    PubMed     Abstract available


  83. CHO D, Milbury K, Liao Y, Pettaway CA, et al
    Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners.
    PLoS One. 2021;16:e0255614.
    PubMed     Abstract available


  84. WEINER F, Schille JT, Hein JI, Wu XF, et al
    Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
    PLoS One. 2021;16:e0256468.
    PubMed     Abstract available


  85. PARK J, Park J, Oh S, Yea JW, et al
    Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer.
    PLoS One. 2021;16:e0257216.
    PubMed     Abstract available


  86. KIM D, Kim DY, Kim JS, Hong SK, et al
    Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    PLoS One. 2021;16:e0256778.
    PubMed     Abstract available


  87. CIMORELLI M, Nieuwland R, Varga Z, van der Pol E, et al
    Standardized procedure to measure the size distribution of extracellular vesicles together with other particles in biofluids with microfluidic resistive pulse sensing.
    PLoS One. 2021;16:e0249603.
    PubMed     Abstract available


  88. TSUZUKI S, Nakanishi S, Tamaki M, Oshiro T, et al
    Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
    PLoS One. 2021;16:e0258160.
    PubMed     Abstract available


  89. MINAMITANI M, Mukai T, Yamashita H, Katano A, et al
    Effects on annual income changes after radical radiotherapy versus after prostatectomy in patients with localized prostate cancer with a specific employment status: A web-based pilot study.
    PLoS One. 2021;16:e0258116.
    PubMed     Abstract available


  90. HASHIMOTO Y, Shiina M, Maekawa S, Kato T, et al
    Suppressor effect of catechol-O-methyltransferase gene in prostate cancer.
    PLoS One. 2021;16:e0253877.
    PubMed     Abstract available


  91. VETRICHELVAN O, Gorjala P, Goodman O Jr, Mitra R, et al
    Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis.
    PLoS One. 2021;16:e0257984.
    PubMed     Abstract available


  92. KOGA F, Ito M, Kataoka M, Fukushima H, et al
    Novel anatomical apical dissection utilizing puboprostatic "open-collar" technique: Impact on apical surgical margin and early continence recovery.
    PLoS One. 2021;16:e0249991.
    PubMed     Abstract available


  93. GEDEBORG R, Styrke J, Loeb S, Garmo H, et al
    Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
    PLoS One. 2021;16:e0255966.
    PubMed     Abstract available


  94. CHUNG JH, Jeong JY, Lee JY, Song W, et al
    Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
    PLoS One. 2021;16:e0249709.
    PubMed     Abstract available


  95. MARKERT L, Holdmann J, Klinger C, Kaufmann M, et al
    Small RNAs as biomarkers to differentiate benign and malign prostate diseases: An alternative for transrectal punch biopsy of the prostate?
    PLoS One. 2021;16:e0247930.
    PubMed     Abstract available


  96. ATHANASIOU A, Tennstedt P, Wittig A, Huber R, et al
    A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    PLoS One. 2021;16:e0259093.
    PubMed     Abstract available


  97. GODTMAN RA, Persson E, Cazzaniga W, Sandin F, et al
    Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study.
    PLoS One. 2021;16:e0253081.
    PubMed     Abstract available


  98. CHOI W, Lee H
    Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
    PLoS One. 2021;16:e0258626.
    PubMed     Abstract available


  99. LUO L, Zhang LL, Tao W, Xia TL, et al
    Prediction of potential prognostic biomarkers in metastatic prostate cancer based on a circular RNA-mediated competing endogenous RNA regulatory network.
    PLoS One. 2021;16:e0260983.
    PubMed     Abstract available


  100. KLOSE K, Packeiser EM, Muller P, Granados-Soler JL, et al
    Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PLoS One. 2021;16:e0257403.
    PubMed     Abstract available


  101. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0262326.
    PubMed     Abstract available


  102. KIM J, Cho S, Park Y, Lee J, et al
    Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.
    PLoS One. 2021;16:e0262017.
    PubMed     Abstract available


  103. VIDAL I, Zheng Q, Hicks JL, Chen J, et al
    GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.
    PLoS One. 2021;16:e0241934.
    PubMed     Abstract available


  104. SYVERSEN IF, Elschot M, Sandsmark E, Bertilsson H, et al
    Exploring the diagnostic potential of adding T2 dependence in diffusion-weighted MR imaging of the prostate.
    PLoS One. 2021;16:e0252387.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: